Quick Answer
Ultragenyx Pharmaceutical Inc. reported Cash and Equivalents of $421.00 million for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $421.00M | +142.0% |
| 2024 | $174.00M | -18.7% |
| 2023 | $214.00M | +61.0% |
| 2022 | $132.94M | -56.8% |
| 2021 | $307.58M | -56.9% |
| 2020 | $713.53M | +64.6% |
| 2019 | $433.58M | +282.2% |
| 2018 | $113.43M | +12.9% |
| 2017 | $100.49M | -37.6% |
| 2016 | $161.12M | +72.2% |
| 2015 | $93.57M | +284.7% |
| 2014 | $24.32M | +227.5% |
| 2013 | $7.43M | -91.4% |
| 2012 | $86.19M | +709.7% |
| 2011 | $10.64M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $202.51M | +34.5% | +14.9% |
| June 30, 2025 | $176.31M | -63.3% | +38.8% |
| March 31, 2025 | $127.06M | +13.2% | -26.9% |
| December 31, 2024 | $173.73M | -18.7% | +15.3% |
| September 30, 2024 | $150.62M | +107.5% | -68.7% |
| June 30, 2024 | $480.69M | +371.0% | +328.2% |
| March 31, 2024 | $112.25M | +30.9% | -47.4% |
| December 31, 2023 | $213.58M | +60.7% | +194.3% |
- Ultragenyx Pharmaceutical Inc. showed an increase of +142.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Ultragenyx Pharmaceutical Inc.’s cash and equivalents has grown by 3854.9% (from $10.64 million to $421.00 million).
- The most recent figure is from Ultragenyx Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: